Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leukine (Sargramostim) in Parkinson's Disease
NCT03790670Phase 1Completed
- Sponsor
- University of Nebraska
- Start
- Jan 2019
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sargramostim in Parkinson's disease (PD), sponsored by University of Nebraska. Primary endpoint: Incidence of Treatment-Associated Adverse Events at 37 months. Started Jan 2019; status: completed.
02
Drugs
sargramostim
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03790670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790670.